Paton and coauthors examined CD8 cell activation in 83 patients with asymptomatic HIV infection who were not taking antiretroviral therapy in a randomized, double-blind, placebo-controlled trial of hydroxychloroquine. In an 8488, Stein and Hsue discuss interventions that target inflammation and immune activation in patients with HIV.
To determine risk of cervical precancer and cancer among human immunodeficiency virus (HIV)-infected women with normal cervical cytology and no evidence of oncogenic human papillomavirus infection, Keller and coauthors followed up 699 women with and without HIV infection enrolled in the Women’s Interagency HIV study.
In a prospective cohort of 638 patients coinfected with human immunodeficiency virus and hepatitis C virus, Limketkai and coauthors investigated the incidence of end-stage liver disease, hepatocellular carcinoma, and death based on baseline hepatic fibrosis and antiviral treatment.
Subramanian and coauthors assess arterial wall inflammation in human immunodeficiency virus using 18fluorine-2-deoxy-D-glucose positron emission tomography in relationship to traditional and nontraditional risk markers, including soluble CD163. See the related Editorial by Stein and Hsue.
Thompson and coauthors provide an update of guidelines recommended by the International Antiviral Society–USA Panel on antiretroviral therapy for HIV-infected adults in developed-world settings.